Next Article in Journal
Hemophagocytic Lymphohistiocytosis and Pelger-Huët Anomaly Associated with Colchicine Intoxication
Previous Article in Journal
Prevalence of Thrombophilic Gene Polymorphisms in an Azari Population of Iran
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 6
Issue 2
10.4081/hr.2014.5288
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib

by
David Sanford
1,*,
Maria MacDonald
2,
Michael Nicolle
2,3 and
Anargyros Xenocostas
1
1
Department of Medicine, Division of Hematology, University of Western Ontario, London, ON N6A 5C1, Canada
2
Department of Oncology, University of Western Ontario, London, ON N6A 5C1, Canada
3
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON N6A 5C1, Canada
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2014, 6(2), 5288; https://doi.org/10.4081/hr.2014.5288 (registering DOI)
Submission received: 7 January 2014 / Revised: 25 February 2014 / Accepted: 24 March 2014 / Published: 19 June 2014

Abstract

We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required.
Keywords: chronic myeloid leukemia; tyrosine kinase inhibitors; adverse drug events chronic myeloid leukemia; tyrosine kinase inhibitors; adverse drug events

Share and Cite

MDPI and ACS Style

Sanford, D.; MacDonald, M.; Nicolle, M.; Xenocostas, A. Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib. Hematol. Rep. 2014, 6, 5288. https://doi.org/10.4081/hr.2014.5288

AMA Style

Sanford D, MacDonald M, Nicolle M, Xenocostas A. Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib. Hematology Reports. 2014; 6(2):5288. https://doi.org/10.4081/hr.2014.5288

Chicago/Turabian Style

Sanford, David, Maria MacDonald, Michael Nicolle, and Anargyros Xenocostas. 2014. "Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib" Hematology Reports 6, no. 2: 5288. https://doi.org/10.4081/hr.2014.5288

APA Style

Sanford, D., MacDonald, M., Nicolle, M., & Xenocostas, A. (2014). Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib. Hematology Reports, 6(2), 5288. https://doi.org/10.4081/hr.2014.5288

Article Metrics

Back to TopTop